BRPI0519209A2 - compostos orgçnicos - Google Patents

compostos orgçnicos

Info

Publication number
BRPI0519209A2
BRPI0519209A2 BRPI0519209-9A BRPI0519209A BRPI0519209A2 BR PI0519209 A2 BRPI0519209 A2 BR PI0519209A2 BR PI0519209 A BRPI0519209 A BR PI0519209A BR PI0519209 A2 BRPI0519209 A2 BR PI0519209A2
Authority
BR
Brazil
Prior art keywords
mono
organic compounds
diaspartate
diglutamate
disuccinate
Prior art date
Application number
BRPI0519209-9A
Other languages
English (en)
Inventor
Olivier Lambert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0519209A2 publication Critical patent/BRPI0519209A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSTOS ORGÂNICOS. A presente invenção refere-se a uma composição farmacêutica para administração parenteral de um sal de um análogo de somatostatina, aspartato, como por exemplo, mono ou diaspartato, lactato, succinato, como por exemplo, mono ou dissuccinato, acetato, glutamato, como por exemplo, mono ou diglutamato, ou citrato, e água, formando um sistema de depósito geleificante, após injeção em contato com um fluido corporal.
BRPI0519209-9A 2004-12-22 2005-12-20 compostos orgçnicos BRPI0519209A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428151.5A GB0428151D0 (en) 2004-12-22 2004-12-22 Organic compounds
PCT/EP2005/013703 WO2006066868A2 (en) 2004-12-22 2005-12-20 Sustained release formulation comprising bisphosphonate

Publications (1)

Publication Number Publication Date
BRPI0519209A2 true BRPI0519209A2 (pt) 2009-01-06

Family

ID=34113101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519209-9A BRPI0519209A2 (pt) 2004-12-22 2005-12-20 compostos orgçnicos

Country Status (19)

Country Link
US (2) US20100029550A1 (pt)
EP (1) EP1830806B1 (pt)
JP (1) JP4977622B2 (pt)
KR (1) KR101335757B1 (pt)
CN (1) CN101072551B (pt)
AR (1) AR051803A1 (pt)
AU (1) AU2005318454B2 (pt)
BR (1) BRPI0519209A2 (pt)
CA (1) CA2585116C (pt)
ES (1) ES2515097T3 (pt)
GB (1) GB0428151D0 (pt)
GT (1) GT200500358A (pt)
MX (1) MX2007007572A (pt)
PE (1) PE20060769A1 (pt)
PL (1) PL1830806T3 (pt)
PT (1) PT1830806E (pt)
RU (1) RU2395274C2 (pt)
TW (1) TW200637612A (pt)
WO (1) WO2006066868A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
US8937152B2 (en) 2007-12-03 2015-01-20 Italfarmaco Spa Non-selective somatostatin analogues
PT2523653T (pt) 2010-01-13 2018-06-28 Ipsen Pharma Sas Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina
US8535544B2 (en) 2010-07-26 2013-09-17 International Business Machines Corporation Structure and method to form nanopore
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
WO2018048609A1 (en) 2016-09-06 2018-03-15 Monell Chemical Senses Center Method of regulating immunity in the intestines
JP7564620B2 (ja) * 2017-03-09 2024-10-09 コーセプト セラピューティクス， インコーポレイテッド カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
AU2022390573A1 (en) * 2021-11-22 2024-05-16 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083305B1 (de) * 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
JP4642946B2 (ja) 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
AU767837B2 (en) * 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
CN1638732A (zh) * 2002-03-04 2005-07-13 研究及应用科学协会股份有限公司 含载体肽的缓释药物制剂
GB0300095D0 (en) 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
WO2010003939A1 (en) * 2008-07-08 2010-01-14 Novartis Ag Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Also Published As

Publication number Publication date
GB0428151D0 (en) 2005-01-26
TW200637612A (en) 2006-11-01
CA2585116C (en) 2014-05-20
PE20060769A1 (es) 2006-09-28
KR101335757B1 (ko) 2013-12-02
ES2515097T3 (es) 2014-10-29
CA2585116A1 (en) 2006-06-29
EP1830806A2 (en) 2007-09-12
US20150038414A1 (en) 2015-02-05
US9303067B2 (en) 2016-04-05
AR051803A1 (es) 2007-02-07
AU2005318454B2 (en) 2009-08-20
KR20070090942A (ko) 2007-09-06
WO2006066868A3 (en) 2006-10-12
WO2006066868A2 (en) 2006-06-29
RU2007128101A (ru) 2009-01-27
JP4977622B2 (ja) 2012-07-18
GT200500358A (es) 2006-08-07
RU2395274C2 (ru) 2010-07-27
CN101072551B (zh) 2013-04-24
PL1830806T3 (pl) 2015-03-31
AU2005318454A1 (en) 2006-06-29
CN101072551A (zh) 2007-11-14
EP1830806B1 (en) 2014-09-03
JP2008524290A (ja) 2008-07-10
MX2007007572A (es) 2007-07-24
PT1830806E (pt) 2014-11-24
US20100029550A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
PE20130589A1 (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
BRPI0519209A2 (pt) compostos orgçnicos
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
NZ597237A (en) Sublingual apomorphine
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
NZ607595A (en) A process for concentration of a polypeptide
HRP20191285T1 (hr) Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti
EP4541418A3 (en) Assays for diagnosing and evaluating treatment options for fabry disease
EP3192506A3 (en) Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
ATE419842T1 (de) Abgabevehikel mit nanoteilchen
DE60116483D1 (de) Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
WO2008001204A3 (en) Transdermal compositions of pramipexole having enhanced permeation properties
SG162744A1 (en) Stable active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
AR074724A1 (es) Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno
GB0624879D0 (en) Treatment of pervasive development disorders
BRPI0800744A2 (pt) composiÇço de inibiÇço de infecÇço por salmonella para pinto e mÉtodo de inibiÇço de infecÇço por salmonella em pintos
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
ATE390126T1 (de) Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben
EP1758923B8 (en) Peptide substance restoring myocardium function
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.